Disease · MONDO_0004995
cardiovascular disorder
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. cardiovascular disorder. Diseases, record MONDO_0004995. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004995
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
ASCVD, CARDIOVASC DIS, CIRCULATORY DISEASE NOS, CVD, CVD, NOS, CVS disease, Cardiovascular Diseases, Cardiovascular Disorders, Cardiovascular disease, NOS, Cardiovascular disease, unspecified, Cardiovascular disorder, NOS, Certain sequelae of myocardial infarction, not elsewhere classified, Circulatory system disease NOS, Circulatory system disease NOS (disorder), DISEASES OF THE CIRCULATORY SYSTEM, Disease affecting entire cardiovascular system, Disease affecting entire cardiovascular system (disorder), Disease of cardiovascular system (disorder), Disease of cardiovascular system, NOS, Disease, Cardiovascular, Diseases, Cardiovascular, Disorder of cardiovascular system (disorder), Disorder of circulatory system, Disorder of circulatory system, NOS, Disorder of the circulatory system, ILL-DEFINED HRT DIS NEC, Ill-defined descriptions and complications of heart disease, OTHER SEQUELAE OF MI NEC, Other diseases of endocardium, Other diseases of endocardium (disorder), Other diseases of pericardium, Other diseases of pericardium (disorder), Other disorders of papillary muscle, Other forms of heart disease, Other forms of heart disease (disorder), Other heart disease, Other heart disease (disorder), Other heart disease NOS, Other heart disease NOS (disorder), Other ill-defined heart disease, Other ill-defined heart disease (disorder), Other ill-defined heart disease NOS, Other ill-defined heart disease NOS (disorder), Other ill-defined heart diseases, Other pericardial disease NOS, Other pericardial disease NOS (disorder), Other sequelae of myocardial infarction, not elsewhere classified, Other specified diseases of pericardium, Other specified pericardial disease NOS, Other specified pericardial disease NOS (disorder), PAPILLARY MUSCLE DIS NEC, PERICARDIAL DISEASE NEC, Unspecified circulatory system disorder, [X]Cardiovascular disease, unspecified, [X]Cardiovascular disease, unspecified (disorder), [X]Other forms of heart disease, [X]Other forms of heart disease (disorder), [X]Other ill-defined heart diseases, [X]Other ill-defined heart diseases (disorder), [X]Other specified diseases of pericardium, [X]Other specified diseases of pericardium (disorder), cardiovascular disease, cardiovascular disease (CVD), cardiovascular system disease, cardiovascular system disease or disorder, circulatory system disease, disease of cardiovascular system, disease of subdivision of hemolymphoid system, disease or disorder of cardiovascular system, disorder of cardiovascular system
- Open Targets
- Highest stage of its drugs
- Approval, for 330 of its 522 drugs, from ATC, DailyMed and TTD
- Open Targets
Drugs522
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ASPIRIN | CHEMBL25 | Small molecule | Approval | TTD | 20 | 18 | 18 | Drugs and targets |
| ATORVASTATIN | CHEMBL1487 | Small molecule | Approval | ATC and TTD | 18 | 14 | 14 | Drugs and targets |
| SIMVASTATIN | CHEMBL1064 | Small molecule | Approval | ATC | 14 | 13 | 13 | Drugs and targets |
| EVOLOCUMAB | CHEMBL2364655 | Antibody | Approval | ATC and DailyMed | 10 | 8 | 8 | Drugs and targets |
| EZETIMIBE | CHEMBL1138 | Small molecule | Approval | ATC | 9 | 8 | 8 | Drugs and targets |
| ROSUVASTATIN | CHEMBL1496 | Small molecule | Approval | ATC | 9 | 8 | 8 | Drugs and targets |
| FENOFIBRATE | CHEMBL672 | Small molecule | Approval | ATC | 7 | 5 | 5 | Drugs and targets |
| HYDROCHLOROTHIAZIDE | CHEMBL435 | Small molecule | Approval | ATC | 7 | 5 | 5 | Drugs and targets |
| ALIROCUMAB | CHEMBL2109540 | Antibody | Approval | ATC | 6 | 5 | 5 | Drugs and targets |
| INCLISIRAN | CHEMBL3990033 | Oligonucleotide | Approval | ATC | 6 | 5 | 5 | Drugs and targets |
1 to 10 of 522
See all 522 drugsTargets282
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB1 | Adrenergic receptor | 30 | Adrenergic receptor agonist; Adrenergic receptor antagonist; Adrenergic receptor beta agonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist; Beta-1 adrenergic receptor inhibitor; Beta-1 adrenergic receptor partial agonist | Approval | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor | 21 | Adrenergic receptor agonist; Adrenergic receptor antagonist; Adrenergic receptor beta agonist; Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist; Beta-2 adrenergic receptor partial agonist | Approval | https://conductscience.org/library/genes/154 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 21 | Voltage-gated L-type calcium channel blocker; Voltage-gated calcium channel blocker | Approval | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 21 | Voltage-gated L-type calcium channel blocker; Voltage-gated calcium channel blocker | Approval | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 21 | Voltage-gated L-type calcium channel blocker; Voltage-gated calcium channel blocker | Approval | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 21 | Voltage-gated L-type calcium channel blocker; Voltage-gated calcium channel blocker | Approval | https://conductscience.org/library/genes/779 | Drugs and targets |
| ADRA1A | Adrenergic receptor | 18 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Adrenergic receptor antagonist | Approval | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 18 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Adrenergic receptor antagonist | Approval | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 18 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Adrenergic receptor antagonist | Approval | https://conductscience.org/library/genes/146 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 14 | Angiotensin-converting enzyme inhibitor | Approval | https://conductscience.org/library/genes/1636 | Drugs and targets |
1 to 10 of 282
See all 282 targetsTrials218
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05214573 | Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk | 386,301 | 2025-10-10 | Type 2 Diabetes, Cardiac Disease | DEXTROSE | Its record names the disease | ClinicalTrials.gov | |
| NCT05073692 | Comparison of Type 2 Diabetes Pharmacotherapy Regimens | 241,981 | 2025-11-21 | Type 2 Diabetes Mellitus, Cardiovascular Diseases | EMPAGLIFLOZIN, EXENATIDE, GLIMEPIRIDE, GLIPIZIDE, LIRAGLUTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01986881 | Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004) | Phase 3 | 8,246 | 2021-02-15 | Type 2 Diabetes Mellitus | ERTUGLIFLOZIN | Its record names the disease | ClinicalTrials.gov |
| NCT00379769 | RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes | Phase 3 | 4,447 | 2009-11-13 | Diabetes Mellitus, Type 2 | METFORMIN, ROSIGLITAZONE | Its record names the disease | ClinicalTrials.gov |
| NCT00377676 | Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes | Phase 3 | 3,095 | 2011-10-28 | Type 2 Diabetes Mellitus | BROMOCRIPTINE MESYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT02207634 | Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects | Phase 3 | 1,974 | 2018-01-16 | Dyslipidemia | EVOLOCUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01042977 | Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease | Phase 3 | 964 | 2013-08-23 | Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control | DAPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov |
| NCT01031680 | Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension | Phase 3 | 922 | 2013-08-23 | Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension, Inadequate Glycaemic Control | DAPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov |
| NCT04807400 | Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support | Phase 3 | 892 | 2024-03-25 | Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol | INCLISIRAN, INCLISIRAN SODIUM | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00862251 | Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED) | Phase 3 | 808 | 2012-03-16 | Cardiovascular Disorder, Diabetes Mellitus | ATORVASTATIN, EZETIMIBE, ROSUVASTATIN, SIMVASTATIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 218
See all 218 trialsComparisons in its trials71
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Aims 1, 2B, and 3 Groups vs Aim 2A Group: deaths from any cause | 22,208 of 386,276 | 0 of 25 | 386,301 | NCT05214573 | Trial comparisons |
| Aims 1, 2B, and 3 Groups vs Aim 2A Group: serious adverse events | 40,642 of 386,276 | 0 of 25 | 386,301 | NCT05214573 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions | 88 of 2,220 | 96 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions | 50 of 2,220 | 63 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions | 88 of 2,220 | 96 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions | 68 of 2,220 | 60 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions | 186 of 2,220 | 191 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
Combined RSG vs Combined MET/SU: Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions | 181 of 2,220 | 188 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events | 321 of 2,220 | 323 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions | 72 of 2,220 | 62 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
1 to 10 of 71
See all 71 comparisons in its trialsPapers from its trials177
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004995
GET https://conductscience.org/api/diseases/v1/MONDO_0004995/drugs?page=2